TABLE 1.

Biological results for 17 cystic fibrosis patients with proven or probable ABPAh

Patient no.Age (yr)GenderaAspergillosis diagnosisSerum sample no.bAntibodies to A. fumigatusTotal IgEf (kIU/liter)No. of Aspergillus colonies in sputum
rAspf4d (kAU/liter)rAspf6d (kAU/liter)IgGc indexIE (precipitin no., enzymatic activitiese)
110MABPA1 (m − 17)<0.10<0.100.37015.5ND
2 (m − 2)<0.10<0.100.583, cat+553ND
3 (m + 7)0.110.101.587, cat+, chym+3,0900
4 (m + 20)0.600.421.532, cat+4220
5 (m + 32)6.522.752.923, cat+ND0
26FABPA6 (m − 17)NDgND0.40NDND
7 (m0)<0.10<0.101.834, cat+2893
8 (m + 13)0.130.132.122, cat+2920
9 (m + 30)3.251.663.372, cat+ND0
10 (m + 40)7.281.70.72, cat+2,1401
314MABPA11 (m0)<0.10<0.103.344, cat+9450
12 (m + 18)0.980.201.483, cat+3620
13 (m + 30)3.091.002.628890
14 (m + 38)2.810.341.1617110
15 (m + 47)0.522.275.343, cat+8390
413FABPA16 (m0)1.620.341.383, cat+1840
17 (m + 6)0.470.110.642, cat+700
18 (m + 14)0.270.10.350330
19 (m + 21)0.11<0.100.580<180
20 (m + 32)0.770.142.153, cat+1380
55MABPA21 (m − 2)<0.100.100.511805ND
22 (m0)3.490.281.775, cat+3,1903
23 (m + 30)3.740.280.6301,6500
24 (m + 48)8.150.553.934,250ND
25 (m + 54)7.211.740.8823,5800
68MABPA26 (m − 12)1.17<0.101.6124030
27 (m − 6)2.79<0.102.292417ND
28 (m0)4.37<0.101.872, cat+7771
29 (m + 6)5.45<0.102.823, cat+7260
30 (m + 12)4.24<0.101.772, cat+9180
710FABPA31 (m − 4)<0.10<0.100.360QI0
32 (m + 2)0.64<0.103.434, cat+2273
33 (m + 11)0.59<0.104.617, cat+2120
34 (m + 12)0.35<0.103.885, cat+142ND
35 (m + 23)<0.10<0.100.660240
818FABPA36 (m − 15)0.80<0.101.5917980
37 (m0)2.56<0.101.923, cat+2,3800
38 (m + 9)0.86<0.101.061, cat+9240
39 (m + 15)1.07<0.101.1328660
40 (m + 26)0.37<0.100.8803380
41 (m + 34)0.58<0.101.1229180
916FABPA42 (m0)<0.10<0.100.826, cat+198ND
43 (m + 7)<0.10<0.100.9241373
44 (m + 15)0.20<0.101.047, cat+1693
45 (m + 31)0.63<0.101.704, cat+, chym+3515
46 (m + 38)1.64<0.101.954, cat+62215
1016FABPA47 (m − 25)<0.10<0.100.030426ND
48 (m + 20)2.03<0.101.804, cat+1,080ND
49 (m + 23)1.03<0.101.813, cat+716ND
50 (m + 34)0.51<0.101.222, cat+612ND
51 (m + 60)0.16<0.103.032, cat+531ND
1118MABPA52 (m0)<0.10<0.103.067, cat+, chym+268ND
53 (m + 12)0.100.272.7834071
54 (m + 19)<0.100.141.565, cat+2725
55 (m + 24)<0.100.183.125, cat+304ND
56 (m + 27)0.110.192.575, cat+4496
128MABPA57 (m0)<0.10<0.101.216, cat+186
1321FABPA58 (m + 84)1.582.040.4806180
1418FProbable ABPA59 (m − 28)<0.10<0.101.132ND1
60 (m − 16)<0.10<0.101.306, cat+ND5
61 (m − 8)<0.10<0.102.044, cat+111
62 (m + 13)<0.10<0.102.357, cat+109
63 (m + 26)<0.10<0.102.706, cat+ND15
1519MProbable ABPA64 (m − 53)<0.10<0.1000243
65 (m − 12)<0.10<0.100.4807922
66 (m0)<0.10<0.101.1431,090ND
67 (m + 13)0.76<0.102.3511,540ND
169FProbable ABPA68 (m − 5)<0.10<0.100.510760
69 (m0)<0.10<0.100.7505261
70 (m + 1)<0.100.240.411, cat+224ND
71 (m + 8)<0.100.100.2701371
72 (m + 23)<0.100.630.3221800
1713MProbable ABPA73<0.10<0.101.1631720
  • a M, male; F, female.

  • b The month of serum sampling (m +/−) in respect to the month of aspergillosis diagnosis (m0) for each patient is given in parentheses.

  • c Anti-Aspergillus ELISA IgG. An index value of >0.75 was considered positive.

  • d Specific IgE against two A. fumigatus recombinants measured by the Pharmacia UniCAP method. A result of >0.1 kAU/liter was considered positive.

  • e IE for precipitin detection. More than 2 precipitin lines was considered positive. Positive enzymatic activities (catalase and chymotrypsin) are indicated (+).

  • f Total IgE measured by the Pharmacia UniCAP method. A result of >500 kIU/liter was considered positive.

  • g ND, not determined.

  • h Positive results are shown in boldface type.